Could AstraZeneca’s COVID Vaccine Still Succeed?

1 min read

Two COVID-19 vaccines are already being given to Americans. But what about AstraZeneca (NASDAQ: AZN), which announced interim efficacy results from a late-stage clinical study of its coronavirus vaccine candidate in November? Could the British drugmaker’s treatment still succeed? In this Motley Fool Live video recorded on Dec. 18, 2020, Healthcare and Cannabis Bureau Chief Corinne Cardina and Fool.com writer Keith Speights discuss what investors should know about AstraZeneca’s next steps.

Continue reading

Leave a Reply

Your email address will not be published.

Previous Story

3 Surefire Stocks to Buy With Your $600 Stimulus Check

Next Story

Is Novavax Stock a Buy?

Latest from Blog